Vinie Kouamou
Overview
Explore the profile of Vinie Kouamou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
90
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chakanetsa R, Chikwati R, Chitungo I, Musarurwa C, Tanyanyiwa D, Manasa J, et al.
AIDS Res Treat
. 2024 Nov;
2024:4620951.
PMID: 39575093
Following the 2018 World Health Organization's (WHO) guidelines on HIV treatment and management, the Zimbabwean government has embraced dolutegravir (DTG)-based regimens as the preferred first-line treatment for people living with...
2.
Mtisi T, Kouamou V, Morse G, Dzinamarira T, Ndhlovu C
J Infect Public Health
. 2024 Aug;
17(9):102500.
PMID: 39173560
Background: Monitoring adherence presents a challenge in adolescents and it is prudent to explore several options for determining their level of adherence. This study sought to determine ART adherence levels...
3.
Bvumbi C, Kouamou V, Kone N, Zaranyika T, Bowora L, Matarira H, et al.
Afr J Lab Med
. 2024 May;
13(1):2373.
PMID: 38725708
What This Study Adds: This study highlights the need for population-specific cut-off HbA1c values in the diagnosis of diabetes mellitus.
4.
Kamurai B, Chikwati R, Vhanda D, Nyamayaro T, Manasa J, Kouamou V
South Afr J HIV Med
. 2024 May;
25(1):1543.
PMID: 38725704
Background: Dolutegravir-based antiretroviral therapy (ART) is currently recommended as the preferred first-line ART in many resource-limited settings. However, little is known about the clinical experience of dolutegravir within a context...
5.
Chu C, Tao K, Kouamou V, Avalos A, Scott J, Grant P, et al.
Viruses
. 2024 Mar;
16(3).
PMID: 38543764
Background: Dolutegravir (DTG) is a cornerstone of global antiretroviral (ARV) therapy (ART) due to its high efficacy and favorable tolerability. However, limited data exist regarding the risk of emergent integrase...
6.
Dzinamarira T, Moyo E, Moyo B, Murewanhema G, Cuadros D, Kouamou V, et al.
Front Public Health
. 2024 Feb;
12:1346027.
PMID: 38420022
No abstract available.
7.
Kouamou V, Washaya T, Mapangisana T, Ndhlovu C, Manasa J
AIDS
. 2024 Jan;
38(5):689-696.
PMID: 38227596
Objective: Dolutegravir (DTG)-based antiretroviral therapy (ART) is being scaled up in Africa. However, clinical experience with DTG and patterns of HIV drug resistance (HIVDR) are sparse in Zimbabwe. We assessed...
8.
Kouamou V, Inzaule S
Pan Afr Med J
. 2023 Dec;
46:32.
PMID: 38145199
Whilst the largely limited health system and funds are already overstretched while responding to multiple epidemics, ongoing vaccine-preventable diseases (VPD) including polio and measles continue to be a public health...
9.
10.
Kouamou V, Washaya T, Ndhlovu C, Manasa J
Viruses
. 2023 Sep;
15(9).
PMID: 37766288
Dolutegravir (DTG) use in combination with tenofovir and lamivudine (TLD) is scaling up in Africa. However, HIV drug resistance (HIVDR) data to DTG remain scarce in Zimbabwe. We assessed the...